224: AI and Computational Pathology in Breast Cancer Care

Send us Fan MailPaper Discussed in this Episode: How artificial intelligence applied to digital pathology could guide treatment personalization in breast cancer. T. Ruelle, T. Grinda, L. Del Mastro, M. Lacroix-Triki, B. Pistilli & G. Gessain. ESMO Real World Data and Digital Oncology 2026.Episode Summary: In this journal club episode, we step into the reality of computational pathology and explore how artificial intelligence is fundamentally transforming breast cancer diagnostics. We examine a comprehensive review detailing how AI not only assists overburdened healthcare systems but also unlocks invisible genomic data straight from a standard $5 hematoxylin-eosin (H&E) glass slide. What happens when a machine can predict complex DNA mutations just by evaluating the structural architecture of cells?In This Episode, We Cover:• The Diagnostic Bottleneck: Understanding the critical worldwide shortage of pathologists colliding with a projected 3.2 million global breast cancer diagnoses by 2050, and why the system is under unprecedented strain.• The Biomarker Battle: Why the human visual cortex struggles to quantify faint immunohistochemistry stains, and how AI acts as a perfect "digital colorimeter". We discuss its near-perfect concordance in assessing crucial biomarkers like Ki-67, ER, PR, PD-L1, and the newly established HER2-low status.• Seeing the Invisible (Predictive AI): How deep learning transcends visual diagnostics to predict treatment outcomes, such as a patient's response to neoadjuvant chemotherapy. We also discuss AI's ability to infer Homologous Recombination Deficiency (HRD) and BRCA1/2 mutations by identifying macroscopic footprints like laminated fibrosis.• Decoding Genomic Assays: The potential to replace expensive, tissue-consuming genomic tests like Oncotype DX with AI models (such as Orpheus) that predict recurrence risk straight from digitized slides, achieving accuracy that rivals the tests themselves.• Roadblocks to Reality: The major clinical friction preventing global rollout. We discuss the steep infrastructure costs of whole-slide scanners, the danger of AI bias across diverse hospital datasets, and the ethical "black box" problem requiring the evolution of transparent, agent-based AI.Key Takeaway: Computational pathology is moving far beyond basic diagnostic assistance. By successfully reading the structural language of biology, AI proves it can extract costly, invisible molecular data from standard biopsies, fundamentally changing the economics and accessibility of global personalized healthcareSupport the showGet the "Digital Pathology 101" FREE E-book and join us!